Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

Choosing the right health insurance cover is not just about the total sum insured, but how the base and super top-up work together. A higher base health cover, such as Rs 10 to 20 lakh, offers ...

As we age, our bodies change, and our eyes are no exception. The good news is that with regular checks and a healthy lifestyle, most people can maintain ...

Duker indicated that EyePoint expects to report top line data for the Phase III LUGANO trial in mid-2026 with LUCIA data to follow closely, complete enrollment in the pivotal Phase III DME program in ...